全文获取类型
收费全文 | 3163篇 |
免费 | 323篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 141篇 |
妇产科学 | 123篇 |
基础医学 | 420篇 |
口腔科学 | 32篇 |
临床医学 | 251篇 |
内科学 | 631篇 |
皮肤病学 | 30篇 |
神经病学 | 258篇 |
特种医学 | 199篇 |
外科学 | 441篇 |
综合类 | 119篇 |
一般理论 | 3篇 |
预防医学 | 338篇 |
眼科学 | 89篇 |
药学 | 210篇 |
1篇 | |
中国医学 | 4篇 |
肿瘤学 | 197篇 |
出版年
2021年 | 39篇 |
2019年 | 40篇 |
2018年 | 38篇 |
2017年 | 42篇 |
2016年 | 37篇 |
2015年 | 47篇 |
2014年 | 52篇 |
2013年 | 84篇 |
2012年 | 135篇 |
2011年 | 110篇 |
2010年 | 76篇 |
2009年 | 85篇 |
2008年 | 121篇 |
2007年 | 102篇 |
2006年 | 121篇 |
2005年 | 92篇 |
2004年 | 92篇 |
2003年 | 101篇 |
2002年 | 98篇 |
2001年 | 106篇 |
2000年 | 82篇 |
1999年 | 87篇 |
1998年 | 62篇 |
1997年 | 61篇 |
1996年 | 56篇 |
1995年 | 56篇 |
1994年 | 44篇 |
1993年 | 54篇 |
1992年 | 88篇 |
1991年 | 79篇 |
1990年 | 71篇 |
1989年 | 78篇 |
1988年 | 86篇 |
1987年 | 83篇 |
1986年 | 86篇 |
1985年 | 80篇 |
1984年 | 52篇 |
1983年 | 54篇 |
1982年 | 51篇 |
1981年 | 45篇 |
1980年 | 32篇 |
1979年 | 39篇 |
1978年 | 42篇 |
1977年 | 40篇 |
1976年 | 32篇 |
1974年 | 27篇 |
1973年 | 32篇 |
1971年 | 24篇 |
1969年 | 22篇 |
1967年 | 27篇 |
排序方式: 共有3501条查询结果,搜索用时 15 毫秒
61.
62.
Susan S. Phillips D. Bruce Baird Vijay V. Joshi Allan J. Rosenberg Edward O. Janosko 《Fetal and pediatric pathology》1997,17(3):497-502
We report a case of Crohn's disease with involvement of the foreskin in a 12-year-old boy. One year previously, on the basis of clinical features (diarrhea with blood, perianal fissures) and histologic examination, a diagnosis of Crohn's disease was made. Subsequently, he developed phimosis and balanitis and underwent circumcision. Sections submitted from the foreskin revealed noncaseating granulomatous inflammation consistent with Crohn's disease. Crohn's disease with involvement of the genitalia is unusual. Only 26 cases including our case have been reported in the scientific literature. We have analyzed these cases with emphasis on gender, age, clinical features, duration of Crohn's disease, and probable mode of spread to the genitalia. Careful examination of sections from genital lesions, including those submitted from the foreskin, is essential to detect small isolated granulomas that may then lead to the diagnosis of inflammatory bowel disease. 相似文献
63.
Formal retrospective case review and sudden infant death 总被引:2,自引:0,他引:2
A review of 24 consecutive sudden infant deaths was undertaken to evaluate the importance of the various stages in the postmortem assessment of such cases. Death in three cases was caused by obvious trauma. Of the remainder, 16 were attributed to sudden infant death syndrome (SIDS), 4 to accidental asphyxia (identified by death scene examination and/or formal case review) and 1 to a lingual thyroglossal duct cyst. Three (14%) of 21 deaths thought to be SIDS after postmortem examination were attributed to asphyxia following subsequent formal case review. 相似文献
64.
65.
Hansen LA; Malarkey DE; Wilkinson JE; Rosenberg M; Woychik RE; Tennant RW 《Carcinogenesis》1998,19(10):1837-1845
We previously reported that papillomas can arise from the follicular
epithelium of v-Ha-ras transgenic TGxAC mice. Since the viable-yellow
mutation (A(vy)) of the mouse agouti gene which regulates coat color
pigmentation by acting within the micro-environment of the hair follicle
has been shown to function as a tumor promoter in the liver, we
hypothesized that it may also play a role in TGxAC skin tumorigenesis.
Endogenous agouti protein product was detected in the outer root sheath of
anagen hair follicles following plucking of the hair shaft, but not in the
interfollicular epithelium, in TGxAC mice on an FVB/N genetic background.
It was also detected in papillomas from these mice produced by
12-O-tetradecanoylphorbol-13-acetate (TPA) treatment or plucking.
Expression of the A(vy) allele in the v-Ha-ras transgenic TGxAC mouse line
results in an approximately 2-fold increase in papilloma development
compared with controls which did not carry the A(vy) allele following
twice-weekly treatment with 1.25, 2.5 or 5.0 microg TPA. In addition,
TPA-treated, papilloma-bearing F1 mice which carried the A(vy) allele, but
not F1 mice which did not carry the A(vy) allele, exhibited a syndrome of
humoral hypercalcemia mediated by parathyroid hormone-related protein
(PTHrP) that led to weight loss, hypercalcemia and hypophosphatemia. Thus,
we conclude that the A(vy) allele can influence the development of skin
tumors and PTHrP-mediated humoral hypercalcemia in v-Ha-ras transgenic
TGxAC mice.
相似文献
66.
67.
Clinical correlations of diffusion and perfusion lesion volumes in acute ischemic stroke 总被引:3,自引:0,他引:3
Baird AE Lövblad KO Dashe JF Connor A Burzynski C Schlaug G Straroselskaya I Edelman RR Warach S 《Cerebrovascular diseases (Basel, Switzerland)》2000,10(6):441-448
The aim of this study was to describe the clinico-radiological correlations of magnetic resonance (MR) perfusion and diffusion-weighted imaging (DWI) abnormalities in ischemic stroke. Eighteen patients had undergone MR imaging and clinical evaluation within 24 h of symptom onset and at or after 7 days. During the first 24 h the volume of perfusion abnormality (measured on the relative mean transit time map) was larger than the DWI lesion in 12/18 patients. In 6/18 patients the DWI lesion volume was larger. Acutely (<24 h) all lesion volumes showed a significant correlation with acute clinical severity measured by the National Institutes of Health Stroke Scale score. The correlations of the hypoperfusion volume (rho = 0.86, p = 0.0001) and the volume 'tissue at risk' (larger than the DWI and perfusion lesion volumes, rho = 0.86, p = 0. 0001) with acute clinical severity were slightly higher than for the DWI lesion volume (rho = 0.76, p = 0.0001). The difference between the volume of tissue at risk (acutely) and the infarct on follow-up T(2)-weighted imaging correlated significantly with change in clinical severity from acute to chronic time points (rho = 0.72, p = 0.001). Such clinico-radiological relationships may support the use of DWI and perfusion MR in decisions concerning the administration and evaluation of stroke therapies. 相似文献
68.
The contribution of platelets and soluble clotting components to clot strength has been the focus of several clinical studies using thromboelastography; it would, therefore, be beneficial to develop an animal model with which to mechanistically approach hemostatic disorders. Thus, we proposed to determine if the contribution of platelet function (G(P), dyne/cm(2)) and soluble components of the coagulation pathway to total clot strength (G(T)) in rabbits were similar to those in humans. Blood was sampled from the ear arteries of conscious rabbits (n = 12); 350 microL of the blood was placed in a thromboelastograph. Ten microliters of normal saline, cytochalasin D (an inhibitor of microtubule function, 10 microM final concentration), or tissue factor (a potent stimulator of platelet function, 0.00625% final concentration) was added to the blood sample, and thromboelastography performed for 1 h. The G(T) (mean +/- SD) was significantly (P < 0.001) different among samples exposed to normal saline, cytochalasin D, or tissue factor, with G(T) values of 7238 +/- 1432, 937 +/- 372, and 16,556 +/- 3314, respectively. G(P) was responsible for 87% and 94% of G(T) in the absence or presence of tissue factor, respectively. G(P) did not significantly correlate with platelet concentration in the absence or presence of tissue factor. The contribution of G(P) to G(T) is similar to that observed in humans. IMPLICATIONS: Rabbits may serve as a model of hemostasis that closely approximates human situations to mechanistically determine the etiology of coagulopathy. The contribution of platelet function to total clot strength is similar to that observed in humans. 相似文献
69.
Edvardas Kaminskas Ann Farrell Sophia Abraham Amy Baird Li-Shan Hsieh Shwu-Luan Lee John K Leighton Hasmukh Patel Atiqur Rahman Rajeshwara Sridhara Yong-Cheng Wang Richard Pazdur 《Clinical cancer research》2005,11(10):3604-3608
PURPOSE: This article summarizes data submitted to the U.S. Food and Drug Administration for marketing approval of azacitidine as injectable suspension (Vidaza, Pharmion Corporation, Boulder, CO) for treatment of patients with myelodysplastic syndrome. EXPERIMENTAL DESIGN: In one phase 3 controlled trial, 191 study subjects were randomized to treatment with azacitidine or to observation; an additional 120 patients were treated with azacitidine in two phase 2 single arm studies. The primary efficacy end point was the overall response rate, defined as complete or partial normalization of peripheral blood counts and bone marrow blast percentages for at least 4 weeks. RESULTS: In the controlled trial, the overall response rate was 15.7% in the azacitidine treatment group; there were no responders in the observation group (P < 0.0001). Response rates were similar in the two single arm studies. During response patients stopped being red cell or platelet transfusion dependent. Median duration of responses was at least 9 months. An additional 19% of azacitidine-treated patients had less than partial responses, most becoming transfusion independent. The most common adverse events attributed to azacitidine were gastrointestinal, hematologic, local (injection site), and constitutional. There were no azacitidine-related deaths. CONCLUSIONS: On May 19, 2004 the U.S. Food and Drug Administration approved azacitidine as injectable suspension for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Full prescribing information is available at http://www.fda.gov/cder/foi/label/2004/050794lbl.pdf. Azacitidine is the first agent approved for treatment of myelodysplastic syndrome. 相似文献
70.
Kazuaki Takabe MD PhD Waddah Al-Refaie Brian Chin Pauline K. Chu Stephen M. Baird Sarah L. Blair 《Journal of gastrointestinal cancer》2005,35(1):83-88
A 58-yr-old male with a history of hepatitis C virus infection, presented with a 2-mo history of intractable left upper abdominal pain. He had fallen from a ladder 2 yr previously, landing on his left side. Abdominal computed tomography identified a large cystic mass in the spleen. The patient was brought to the operating room with a presumptive diagnosis of symptomatic, post-traumatic, false cyst of the spleen. Instead, at surgery, a splenic mass with dense adhesions to the diaphragm and stomach was found. On final histological analysis, it was diagnosed to be a large B-cell lymphoma. Despite its rarity, gastroenterologists and surgeons should be aware of large B-cell lymphoma when encountering cystic lesions of the spleen, because the management of benign cystic disease is usually nonsurgical. 相似文献